The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation.
Watanabe M, Yakushijin K, Funakoshi Y, Ohji G, Hojo W, Sakai H, Saeki M, Hirakawa Y, Matsumoto S, Sakai R, Nagao S, Kitao A, Miyata Y, Koyama T, Saito Y, Kawamoto S, Ito M, Murayama T, Matsuoka H, Minami H.
Watanabe M, et al. Among authors: kawamoto s.
Vaccines (Basel). 2022 Jan 21;10(2):158. doi: 10.3390/vaccines10020158.
Vaccines (Basel). 2022.
PMID: 35214617
Free PMC article.